Featured Press Releases

Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA, according to Currax Pharmaceuticals

Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA, according to Currax Pharmaceuticals

Bloomage 2024 Mid-Year Report: International raw material sales exceed domestic Chinese market sales for the first time

Bloomage 2024 Mid-Year Report: International raw material sales exceed domestic Chinese market sales for the first time

  • 12 Sep 2024

Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, showcased...

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Chromatin Bioscience

Chromatin Bioscience's synthetic promoter enables EsoBiotec's ESO-T01 CAR-T therapy to progress to clinical trials

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

  • Tonix Pharmaceuticals Holding Corp.
  • 30 Jan 2026
China approves Libevitug, first-in-class therapy for hepatitis D

China approves Libevitug, first-in-class therapy for hepatitis D

  • Huahui Health Ltd.
  • 28 Jan 2026
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

  • Johnson & Johnson
  • 27 Jan 2026
Correction — Privo Technologies

Correction — Privo Technologies

  • Privo Technologies
  • 26 Jan 2026
HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

  • HanchorBio Inc.
  • 26 Jan 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.